medigraphic.com
Academia Mexicana de Neurología, A.C.

2010, Number 3

<< Back Next >>

Rev Mex Neuroci 2010; 11 (3)

Devic’s neuromyelitis optica: case report

Chiquete E, Ochoa-Guzmán A, Navarro-Bonnet J, Gutiérrez-Plascencia P, Ruiz-Sandoval JL

Language: Spanish
References: 25
Page: 234-239
PDF size: 158.27 Kb.


ABSTRACT

Devic’s neuromyelitis optica is an infrequent clinical condition characterized by the combination, rarely simultaneous, of monophasic or recurrent episodes of optic neuritis and longitudinally extensive transverse myelitis. It is autoimmune and demyelinating in nature, and due to its recurrent behavior, it was considered in the past as an unusual variant of multiple sclerosis (MS). However, characteristics in clinical presentation and particularly very recent discoveries have permitted to better characterized Devic’s disease and to distinguish it from MS. Specially, it has been described the autoimmune substrate of Devic’s disease, characterized by the presence of autoantibodies against aquaporin-4 (AQP4). Here we present the case of a 49-year-old Hispanic white woman whose first event was an optic neuritis that appeared 5 years before definite diagnosis could be done, when an event of an anti-AQP4-positive acute transverse myelitis occurred. To our knowledge, this is the first description in the Spanish literature of a typical neuromyelitis optica case with anti-AQP4 evidence. Here it is also presented the imagenological and clinical evolution of this paradigmatic case, with a brief review on the diagnosis and management of this entity.


REFERENCES

  1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-15.

  2. Pittock SJ. Neuromyelitis optica: a new perspective. Semin Neurol 2008; 28: 95-104.

  3. Weinshenker BG, Wingerchuk DM. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol 2008; 318: 343-56.

  4. Barriga JD, Roncallo Del Portillo A. Neuromielitis óptica: Estado del arte. Salud Uninorte. Barranquilla (Col.) 2007; 23: 204-19.

  5. Chiquete E, Navarro-Bonnet J, Ayala-Armas R, Gutiérrez-Gutiérrez N, Solórzano-Meléndez A, Rodríguez-Tapia D, Gómez-Rincón M, et al. Neuromielitis óptica: Una actualización clínica. Rev Neurol 2010 [En prensa].

  6. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-12.

  7. Sebastián de la Cruz F, López-Dolado E. [Devic’s optic neuromyelitis: analysis of 7 cases]. Rev Neurol 1999; 28: 476-82.

  8. Echevarría G, Tróccolli G, D’Annuncio E, Gutiérrez O. [Devic’s optic neuromyelitis: presentation as an inflammatory spinal tumour]. Rev Neurol 2001; 33: 41-4.

  9. Bueno V, Hernández M, Ponce MA, Guerrero AL. [Diagnostic difficulties in Devic’s neuromyelitis]. Rev Neurol 1999; 28: 341-2.

  10. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F; Spanish- Italian NMO Study Group. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 2007; 254: 1233-7.

  11. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG. Neuromielytis optica and non-organ specific autoimmunity. Arch Neurol 2008; 65: 78-83.

  12. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53: 1107-14.

  13. O’Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, McDonald WI, Miller DH. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60: 382-87.

  14. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60: 848-53.

  15. Ali EN, Buckle GJ. Neuroimaging in multiple sclerosis. Neurol Clin 2008; 27: 203-19.

  16. Gómez-Argüelles JM, Sánchez-Solla A, López-Dolado E, Díez-De la Lastra E, Florensa J. Mielitis transversa aguda: revisión clínica y algoritmo de actuación diagnóstica. Rev Neurol 2009; 49: 533-40.

  17. Pandit L. Transverse myelitis spectrum disorders. Neurol India 2009; 57: 126-33.

  18. Krampla W, Aboul-Enein F, Jecel J, Lang W, Fertl E, Hruby W, et al. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 2009; 19: 2535-43.

  19. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-9.

  20. Okamoto T, Ogawa M, Lin Y, Murata M, Miyake S, Yamamura T. Treatment of neuromyelitis optica: Current debate. Ther Adv Neurol Disord 2008; 1: 43-52.

  21. Cree B. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep 2008; 8: 427-33.

  22. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, Itoyama I. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007; 13: 968-74.

  23. Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, Bakshi R. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006; 63: 957-63.

  24. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-8.

  25. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007; 252: 57-61.




2020     |     www.medigraphic.com